dc.contributor.author | Babaei, H | |
dc.contributor.author | Ebrahimi, F | |
dc.contributor.author | Mojarrad, JS | |
dc.contributor.author | Azarmi, Y | |
dc.contributor.author | Gharehbagheri, A | |
dc.date.accessioned | 2018-08-26T09:44:49Z | |
dc.date.available | 2018-08-26T09:44:49Z | |
dc.date.issued | 2011 | |
dc.identifier | 10.5681/apb.2011.002 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58693 | |
dc.description.abstract | Introduction: DHPEE is a newly synthesized compound by merging the key structural elements in an angiotensin receptor blocker (Telmisartan) with key structural elements in 1,4- dihydropyridine calcium channel blocker (Nifedipine). In this study, we examined dual calcium channel blocking and AT1 antagonist activity for DHPEE. Methods: The functional inhibitory characteristics of DHPEE were studied in vitro in rat thoracic aorta preparations precontracted by phenylephrine (1?M) or KCl (80?M) or Ang II in normal or calcium-free solutions. Results: Concentration-dependent significant relaxation was observed in aortic rings precontracted with phenylephrine, KCl or Ang II. The tension increment produced by increasing external calcium was also reduced by DHPEE. DHPEE caused a marked decrease in the maximal contractile response of the vasoactive agents and shifted their concentration-response curves to the right. Conclusion: DHPEE possesses dual characteristics and cause vasorelaxation by blocking the L-type calcium channels and blocking Ang II receptors (AT1) in rat aortic smooth muscle. ط¢آ© 2011 by Tabriz University of Medical Sciences. | |
dc.language.iso | English | |
dc.relation.ispartof | Advanced Pharmaceutical Bulletin | |
dc.subject | angiotensin receptor | |
dc.subject | calcium | |
dc.subject | calcium channel L type | |
dc.subject | dihydropyridine derivative | |
dc.subject | dihydropyridine ethyl ester | |
dc.subject | losartan | |
dc.subject | nifedipine | |
dc.subject | pentobarbital | |
dc.subject | unclassified drug | |
dc.subject | animal tissue | |
dc.subject | aorta media | |
dc.subject | article | |
dc.subject | controlled study | |
dc.subject | dose response | |
dc.subject | drug activity | |
dc.subject | drug mechanism | |
dc.subject | drug potency | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | drug tolerability | |
dc.subject | female | |
dc.subject | in vitro study | |
dc.subject | male | |
dc.subject | membrane depolarization | |
dc.subject | nonhuman | |
dc.subject | patient compliance | |
dc.subject | rat | |
dc.subject | thoracic aorta | |
dc.subject | vasodilatation | |
dc.title | Vasorelaxant effect of a newly synthesized dihydropyridine ethyl ester (DHPEE) on rat thoracic aorta: Dual mechanism of action | |
dc.type | Article | |
dc.citation.volume | 1 | |
dc.citation.issue | 1 | |
dc.citation.spage | 10 | |
dc.citation.epage | 17 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.5681/apb.2011.002 | |